/

Ricerca sul cancro

/

Профилирование чувствительности к таргетной терапии в органоидах EGFR-мутантного НМРЛ, полученных из пациента

JoVE Journal
Ricerca sul cancro

This content is Free Access.

JoVE Journal Ricerca sul cancro

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Please note that all translations are automatically generated. Click here for the English version.

Профилирование чувствительности к таргетной терапии в органоидах EGFR-мутантного НМРЛ, полученных из пациента

3,451 Views

•

08:52 min

•

November 22, 2021

DOI:

10.3791/63039-v

DOI:

10.3791/63039-v

•

08:52 min

November 22, 2021

•

2 Views

Dora Barbosa Rabago^2,3, Collin M. Blakely², Franziska Haderk^2,3, Trever G. Bivona^2,3

¹Department of Medicine,University of California, San Francisco, ²Helen Diller Family Comprehensive Cancer Center,University of California, San Francisco, ³Department of Cellular and Molecular Pharmacology,University of California, San Francisco

Tags

Organoids EGFR-mutant NSCLC Targeted Therapies Matrigel Cell Culture Dissociation Trypsinization Centrifugation Cell Counting Cell Suspension 96-well Plate

Read Article